Mechanism by which the lectin actinohivin blocks HIV infection of target cells.
Various lectins have attracted attention as potential microbicides to prevent HIV transmission. Their capacity to bind glycoproteins has been suggested as a means to block HIV binding and entry into susceptible cells. The previously undescribed lectin actinohivin (AH), isolated by us from an actinomycete, exhibits potent in vitro anti-HIV activity by binding to high-mannose (Man) type glycans (HMTGs) of gp120, an envelope glycoprotein of HIV. AH contains 114 aa and consists of three segments, all of which need to show high affinity to gp120 for the anti-HIV characteristic. To generate the needed mechanistic understanding of AH binding to HIV in anticipation of seeking approval for human testing as a microbicide, we have used multiple molecular tools to characterize it. AH showed a weak affinity to Man alpha(1-2)Man, Man alpha(1-2)Man alpha(1-2)Man, of HMTG (Man8 or Man9) or RNase B (which has a single HMTG), but exhibited a strong and highly specific affinity (K(d) = 3.4 x 10(-8) M) to gp120 of HIV, which contains multiple Man8 and/or Man9 units. We have compared AH to an alternative lectin, cyanovirin-N, which did not display similar levels of discrimination between high- and low-density HMTGs. X-ray crystal analysis of AH revealed a 3D structure containing three sugar-binding pockets. Thus, the strong specific affinity of AH to gp120 is considered to be due to multivalent interaction of the three sugar-binding pockets with three HMTGs of gp120 via the "cluster effect" of lectin. Thus, AH is a good candidate for investigation as a safe microbicide to help prevent HIV transmission.
Tanaka
Haruo
H
Faculty of Pharmacy and College of Science and Engineering, Iwaki Meisei University, Iwaki, Fukushima 970-8551, Japan. tanakaha@msn.com
Chiba
Harumi
H
Inokoshi
Junji
J
Kuno
Atsushi
A
Sugai
Takahiro
T
Takahashi
Atsushi
A
Ito
Yukishige
Y
Tsunoda
Masaru
M
Suzuki
Kaoru
K
Takénaka
Akio
A
Sekiguchi
Takeshi
T
Umeyama
Hideaki
H
Hirabayashi
Jun
J
Omura
Satoshi
S
D001426:Bacterial Proteins / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D001665:Binding Sites; D002352:Carrier Proteins / Q000493:pharmacokinetics / Q000494:pharmacology; D018360:Crystallography, X-Ray; D015699:HIV Envelope Protein gp120 / Q000737:chemistry; D023581:HIV Fusion Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000187:drug effects* / Q000472:pathogenicity / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D037102:Lectins / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D008358:Mannose / Q000737:chemistry; D008362:Mannosides / Q000737:chemistry; D008958:Models, Molecular; D017434:Protein Structure, Tertiary
D001426:Bacterial Proteins; D002352:Carrier Proteins; D015699:HIV Envelope Protein gp120; D023581:HIV Fusion Inhibitors; D037102:Lectins; D008362:Mannosides; C424136:actinohivin protein, actinomycete; C514793:gp120 protein, Human immunodeficiency virus 1; C107733:cyanovirin N; D008358:Mannose